Item 8.01. Other Events.
On September 29, 2020, Zosano Pharma Corporation (the "Company") received a
discipline review letter ("DRL") from the U.S. Food and Drug Administration
("FDA") in connection with the Qtrypta™ (zolmitriptan transdermal microneedle
system) 505(b)(2) New Drug Application ("NDA"). A DRL letter is used by the FDA
to convey preliminary thoughts on deficiencies identified during the NDA review
with respect to a particular review discipline.
The DRL described two concerns with respect to the clinical pharmacology section
of the NDA. First, the FDA raised questions regarding unexpected high plasma
concentrations of zolmitriptan observed in five study subjects from two
pharmacokinetic studies, and how the data from these subjects affect the overall
clinical pharmacology section of the application. Second, the FDA raised
questions regarding differences in zolmitriptan exposures observed between
subjects receiving different lots of Qtrypta in the Company's clinical trials.
Although a DRL reflects preliminary comments that are subject to change, and
does not reflect the FDA's final decision on the NDA, approval of Qtrypta by the
Prescription Drug User Fee Act goal date of October 20, 2020 is not expected
given the letter.
As of September 29, 2020, the Company had approximately $43.4 million in cash
and cash equivalents. This cash and cash equivalents information is preliminary
and subject to completion, including the completion of customary financial
statement closing and review procedures for the quarter ending September 30,
2020. As a result, the preliminary information set forth above reflects the
Company's preliminary estimate with respect to such information, based on
information currently available to management, and may vary from the Company's
actual cash and cash equivalents as of September 29, 2020.
Forward-Looking Statements
This report contains forward-looking statements. All statements other than
statements of historical facts contained herein are forward-looking statements
reflecting the current beliefs and expectations of management made pursuant to
the safe harbor provisions of the Private Securities Litigation Reform Act of
1995, including, but not limited to, statements regarding the Company's cash and
cash equivalents as of September 29, 2020 and the Company's expectations with
respect to approval of Qtrypta by the Prescription Drug User Fee Act goal date.
Such forward-looking statements involve known and unknown risks, uncertainties,
and other important factors that may cause the Company's actual results,
performance, or achievements to be materially different from any future results,
performance, or achievements expressed or implied by the forward-looking
statements. For a further description of the risks and uncertainties that could
cause actual results to differ from those expressed in these forward-looking
statements, as well as risks relating to the Company's business in general, see
the most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q
filed with the Securities and Exchange Commission. The Company does not plan to
publicly update or revise any forward-looking statements contained in this
report, whether as a result of any new information, future events, changed
circumstances or otherwise, except as required by law.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses